Advertisement

Topics

Genentech's Breast Cancer Treatment Granted Priority Review

10:07 EDT 29 Sep 2017 | PharmPro

News
Related Biotechnology, Pharmaceutical and Healthcare News
FDA grants Priority Review for Genentech’s Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer. The supplemental Biologics License Application is based on results of the Phase III APHINITY study.
Contributed Author: 
Genentech
Topics: 
Drug Development

Original Article: Genentech's Breast Cancer Treatment Granted Priority Review

NEXT ARTICLE

More From BioPortfolio on "Genentech's Breast Cancer Treatment Granted Priority Review"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search
Advertisement
 

News Quicklinks

Search Biotech, Medical and Healthcare News

Popular Biotech, Medical and Healthcare News

Biotech News by Article Type

Biotech News by Location

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches


BioPortfolio Limited Social Media
Publish Content Agreements
Tools Help

HON Code certificate This site complies with the HONcode standard for trustworthy health information:
Verify here.

The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored BioPortfolio Limited with offices at Stafford House, 10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters at: priority@bioportfolio.com.
All rights reserved. All other trademarks recognized. Copyright © 1997-2017 BioPortfolio Limited. Site developed by Alacrify Ltd.